Neuromodulation for the treatment of primary headache syndromes by Hoffmann, Jan & May, Arne
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1080/14737175.2019.1585243
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Hoffmann, J., & May, A. (2019). Neuromodulation for the treatment of primary headache syndromes. Expert
Review of Neurotherapeutics, 19(3), 261-268. https://doi.org/10.1080/14737175.2019.1585243
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
1 
 
Neuromodulation for the treatment of  
primary headache syndromes 
 
Jan Hoffmann1,2 & Arne May1 
 
1)Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, 
Hamburg, Germany 
 
2)Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, 
London, United Kingdom 
 
 
Keywords: Cluster headache, External trigeminal nerve stimulation, Headache, Migraine, 
Neuromodulation, Non-invasive vagal nerve stimulation, Occipital nerve stimulation, Sphenopalatine 
ganglion stimulation, Transcranial magnetic stimulation 
Word count abstract: 200 words 
Word count main text: 5006 words 
References: 60 
 
Corresponding author 
Prof. Dr. med. Arne May 
Department of Systems Neuroscience 
University Medical Center Hamburg-Eppendorf 
Martinistrasse 52 
20246 Hamburg 
Germany 
Tel: +49-40-7410-59189 
Fax: +49-40-7410-59955 
a.may@uke.de 
2 
 
Abstract 
 
Introduction 
Neuromodulation techniques play an increasing role in the treatment of primary headaches. While 
initially reserved for refractory cases they are now increasingly taken into consideration in earlier 
treatment phases and in non-refractory situations. One of the main reasons of this paradigm shift is that 
most neuromodulation techniques are better tolerated as compared to the majority of pharmacological 
approaches. However, these techniques have their limitations that should be considered.  
 
Areas covered 
The review provides an overview of the available techniques and their therapeutic rationale as well as 
on the evidence for their efficacy and their limitations. The review covers these aspects for non-invasive 
vagal nerve stimulation, sphenopalatine ganglion stimulation, external trigeminal nerve stimulation, 
occipital nerve stimulation as well as single-pulse and repetitive-pulse transcranial magnetic stimulation.  
 
Expert commentary 
Most of the evidence is based on open-label studies. Sham devices used in controlled studies remain 
problematic as they either do not produce the paresthesias perceived during stimulation or induce some 
degree of stimulation. Invasive techniques require a surgical intervention with all the potential 
complications that may arise.  
In summary some of the techniques provide an effective expansion of available treatment options but 
their indication should be thoroughly evaluated before treatment is considered.  
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Introduction 
Neuromodulation techniques are becoming increasingly important for the treatment of several primary 
headaches. With the availability of a range of invasive and non-invasive approaches and the increasing 
evidence on their efficacy, they represent a valuable expansion of the therapeutic armamentarium. 
From a patients’ perspective these treatments are well accepted as patients increasingly seek non-
pharmacological treatments given that currently available acute and preventive medications frequently 
induce unwanted side-effects that may lead to treatment discontinuation. Nevertheless, 
neuromodulation techniques are still seen as rather unconventional and their use is limited by the fact 
that in many countries most of the devices are not reimbursed by health care insurance. As their cost is 
usually relatively high, the long-term use of most of the devices exceeds the financial capabilities of 
most patients.  
However, the lack of reimbursement is not simply based on the health care providers' responsibility to 
limit health care expenses. Clinical trials on these devices commonly have methodological shortcomings 
that are inherent to their mode of action. Initially many studies were uncontrolled due to the lack of 
adequate sham devices. While this problem has been solved by most of the manufacturers the utility of 
sham devices is limited as the majority of neuromodulation devices cause sensory disturbances 
(paresthesia or hypesthesia) during the stimulation, whereas the sham devices commonly do not induce 
these sensations. Some companies have addressed this problem by stimulating with modified 
stimulation parameters or subthreshold stimulations with lower amplitudes that do not induce sensory 
alterations but this approach bears the risk that these sham devices may already have a limited effect 
that could affect the difference to the verum group, thereby falsely rendering the treatment ineffective.  
Despite these difficulties, the quality of the data has improved substantially and slowly but steadily it 
becomes clearer which technique may offer a useful alternative and with technique does not.  
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In this review we will provide an overview and an interpretation of the existing data on each of the 
neuromodulatory techniques currently available for the treatment of primary headaches.  
 
Non-invasive vagal nerve stimulation 
Non-invasive vagal nerve stimulation (nVNS) (GammaCore®) has been developed for the acute and 
preventive treatment of migraine and cluster headache. In this stimulation procedure a small handheld 
device is placed on the neck on the ipsilateral side to the head pain; it is turned on by the patient who 
then increases the amplitude of stimulating current until a light tingling sensation is perceived on the 
skin. The device stimulates the area and automatically turns off after 120 seconds. Depending on the 
treatment protocol stimulation can be repeated after a brief pause on the same side, on the 
contralateral side for abortive treatment. In case of a preventive intervention, treatment is following a 
fixed schedule two to three times daily. The pathophysiological rationale is, that the externally applied 
current stimulates the vagal nerve. This stimulation is thought to reduce neuronal activity in the 
trigeminocervical complex of the brainstem(1), a key relay center that passes nociceptive information 
from the peripheral part of the trigeminovascular system to higher processing centers(2-4), as well as 
well as in the autonomic parasympathetic pathway that plays a pivotal role in cluster headache and 
other trigemino-autonomic cephalalgias(5). However, given the widespread distribution of the applied 
current and the very limited amount of solid experimental data, there is still substantial uncertainty of 
the influenced nociceptive pathways. The molecular mechanisms that are potentially affected remain 
unknown.  
 
nVNS in migraine 
Since its development a large number of clinical trials have been conducted to prove its efficacy in 
migraine and cluster headache but unfortunately much of the available data is contradictory. For the 
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acute treatment of migraine the device was first studied in an open-label design in which patients 
stimulated up to three consecutive attacks each with two right-sided stimulations of 120 seconds 
separated by an stimulation-free interval of 3 minutes within 20 minutes if the onset of mild or 
moderate pain(6). The results suggested efficacy with 64.6 % of patients experiencing pain relief and 
39.6 % being pain free two hours  after stimulation(6). Since the results were based on an uncontrolled 
study-design (no sham group), a randomized, sham-controlled trial (RCT) followed (PRESTO trial) to 
confirm this finding. However, the RCT showed efficacy at the 30 and 60 minute time points but failed to 
do so at the 120 minute time point which was the primary endpoint (pain free at two hours)(7).  
The clinical trials to prove its efficacy in the preventive treatment of migraine shared the same fate. In 
the initial open-label trial (no sham group) a bilateral self-treatment of 20 minutes twice daily over 3 
months led to a significant reduction of migraine and headache days in patients with episodic and 
chronic migraine(8) but these results could not be confirmed in the RCT that followed (EVENT study)(9). 
The sham-controlled EVENT study which involved a two-month randomized period followed by a six-
month open-label phase clearly failed to reduce monthly migraine days in the randomized phase. Only 
at the last time point of the open-label phase a weak significance was observed although it is likely that 
this finding is artificial as only 15 patients reached this time-point and it may be assumed that dropped 
out were those that had no effect.  
 
nVNS in cluster headache 
For the assessment of efficacy in the acute treatment of cluster headache the sham-controlled ACT1 trial 
was conducted(10). In this study patients stimulated unilaterally (side of pain) three consecutive times 
each lasting 120 seconds separated by a stimulation-free interval of one minute. Sham stimulation was 
performed applying a low-frequency (0.1 Hz) biphasic signal that does not stimulate the vagus nerve. 
The response (proportion of patients who achieved a pain intensity of zero or one on a five-point scale 
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without the use of rescue medication) was assessed 15 minutes after stimulation. While the study failed 
to prove efficacy in the complete study population it revealed that nVNS was effective in the acute 
treatment of patients with episodic but not in those with chronic cluster headache. To confirm these 
findings a second RCT (ACT2 study) was conducted, which showed the same result using a slightly 
different primary endpoint (pain free at 15 minutes)(11). Again nVNS was only effective in the acute 
treatment of episodic but not in chronic cluster headache. While these findings were intensively 
discussed in the field as they are difficult to explain with the current understanding of the 
pathophysiology of cluster headache, the studies on the preventive treatment of cluster headache using 
the monoclonal antibodies against calcitonin gene-related peptide (CGRP) galcanezumab and 
fremanezumab follow the same pattern (i.e. efficacy in episodic but not in chronic cluster headache). 
However, it has to be considered that these were preventive treatment approaches whereas the nVNS 
findings were obtained in an acute treatment design.  
For the efficacy of nVNS in the preventive treatment of chronic cluster headache only data derived from 
an open-label study (PREVA study) exists(12). In this study a right-sided stimulation of three consecutive 
stimulations of 120 seconds separated by stimulation-free intervals of five minutes, applied twice daily 
over four weeks as an add on-therapy to standard of care therapy, proved to be superior to standard of 
care therapy without additional nVNS. An RCT on the preventive treatment of episodic or chronic cluster 
headache does not yet exist.  
 
nVNS in other trigeminoautonomic cephalalgias 
Tso et al.(13) explored the potential efficacy of nVNS in indomethacin-sensitive trigeminoautonomic 
cephalalgias (TAC), namely chronic paroxysmal hemicrania and hemicrania continua. All observed 
patients were responsive to indomethacin but either had to reduce or even discontinue the treatment 
due to adverse effects so that in this study in some patients nVNS was used as a monotherapy, in some 
7 
 
as an add-on therapy to indomethacin used at the maximum tolerated dose. Of the nine patients with 
hemicrania continua and the six patients with chronic hemicrania continua had a significant 
improvement of their condition while only four patients (2 with hemicrania continua and two with 
chronic paroxysmal hemicrania) had no response to nVNS(13). Sham-controlled studies are clearly 
needed to confirm these findings.  
 
Sphenopalatine ganglion stimulation 
The sphenopalatine ganglion (SPG) stimulation (Pulsante®) was developed initially for the acute 
treatment of cluster headache. In this neurostimulation technique a small electrode is implanted 
through the oral cavity into the close vicinity of the SPG. After the surgical intervention and a recovery 
period of four weeks, patients receive a handheld device to perform an on-demand activation of the 
electrode(14). To do so patients have to hold the device during an attack onto their cheek to activate 
the electrode and induce pain relief. The main advantage of this induction-based approach is that the 
battery is located in the handheld device and not in the electrode so that no surgical revisions are 
required for the exchange of batteries. The downside of this method is that patients have to hold the 
device onto their cheek during the entire stimulation period (15-20 minutes) which is not always easy 
given the excruciating severity of the headache.  
The pathophysiological rationale of this technique is that the applied high-frequency stimulation of the 
SPG inhibits the neuronal activity of the parasympathetic arm of the trigeminoautonomic reflex which is 
thought to play an essential role in the pathophysiology of cluster headache(4, 5, 15, 16).  
The clinical efficacy of SPG stimulation in cluster headache has been demonstrated in the sham-
controlled pathway CH-1 study(17). In this study 28 patients with refractory chronic cluster headache 
used the handheld device during 30 attacks or until a maximum treating period of eight weeks was 
completed. Patients were instructed to stimulate 15 minutes during attacks that had at least moderate 
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intensity and refrain from using acute medications in this period. The device randomly (1:1:1) delivered 
either a full stimulation, a subthreshold stimulation (85 % of the amplitude that provoked a sensory 
perception) or no stimulation. The study reached its primary endpoint defined as pain-relief within 15 
minutes of the start of neurostimulation. The probability of pain relief after 15 minutes reached 67.1 % 
compared to 7.4 % under sham stimulation while the probability of being pain free after 15 minutes of 
stimulation was 34.1 % compared to 1.5 % after sham stimulation. In 12 out of the 28 patients a 
reduction in attack frequency was observed. In these patients attack frequency was reduced by 88 %. In 
total the CH-1 trial showed that 68 % of the patients receiving full stimulation had either an acute 
response, a frequency response, or both. With respect to the observed adverse events, the majority of 
patients reported a loss of sensation in maxillary nerve regions that was mostly transient as 65 % of the 
recorded events resolved within three months(17). A second RCT (NCT02168764) has been conducted in 
the United States to confirm these findings but the results have not been published yet.  
The long-term follow-up of patients under SPG-stimulation revealed that the acute and preventive 
effects are consistent in the vast majority of patients over the entire observational period of 24 
months(18). The same applies to the type of effect the SPG-stimulation had on a given patient. For 
example if the patient had only an acute but no preventive effect from SPG-stimulation he was likely to 
have only that acute effect after 24 months. The same applied for patients showing only a preventive 
effect or those showing both, an acute and a preventive effect(18). Beyond that the study showed that a 
substantial amount of patients that entered the study with a therapy-refractory chronic cluster 
headache switched to an episodic form allowing them to reduce or even discontinue their preventive 
medication(19). Taken together, based on the clinical data available at this point, the effect of SPG-
stimulation is effective and consistent making it an attractive therapeutic option in patients with 
therapy-refractory chronic cluster headache.  
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External trigeminal nerve stimulation 
The external trigeminal nerve stimulation (eTNS) has been developed for the acute and preventive 
treatment of migraine. In this technique a small neurostimulation device (Cefaly® device) is placed on 
the forehead and stimulations is performed with rectangular biphasic symmetrical pulses. For the acute 
treatment of migraine stimulation is performed with a pulse frequency of 100 Hz for 60 minutes, for the 
preventive treatment a frequency of 60 Hz is used and stimulation is performed daily for 20 minutes. 
The maximum stimulation intensity for both treatment types is 16 mA. The precise mode of action is 
unknown but data from imaging studies based on FDG-PET and fMRI suggest functional changes in the 
orbitofrontal cortex and the rostral anterior cingulate cortex(20, 21).  
Efficacy data for eTNS in the acute treatment of migraine relies on an open-label data study as an RCT 
does not exist. In the study published by Chou et al.(22), 30 patients suffering from an acute attack of 
migraine with or without aura, treated their attack for one hour with the Cefaly® device. Primary 
outcome parameter was the change in pain intensity after 1 hour compared to baseline. The 
intervention led to reduction of headache intensity by 57.1% compared to baseline (reduction of 3.22 ± 
2.40 on a VAS ranging from 0-10). The effect remained significant one hour after the end of the 
stimulation period with none of the patients requiring rescue medication at this time point. Even after 
24 hours only 65.4% of patients made use of a rescue medication. While the study clearly shows that 
eTNS may be effective in the acute treatment of migraine the data rely on an open-label study with all 
the inherent shortcomings of a study without a sham group. Therefore an RCT is needed to confirm 
these results.  
In contrast for the preventive treatment of migraine a RCT does exist, the PREMICE study(23). In this 
study 67 patients were randomized with 34 patients receiving verum stimulation and 33 patients 
receiving sham stimulation. Compared to verum stimulation sham stimulation was performed using a 
lower pulse width of 30 μs (compared to 250 μs in verum), a frequency of 1 Hz (instead of 60 Hz) and an 
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intensity of 1 mA (instead of 16 mA). In both groups daily stimulation sessions lasted 20 minutes. 
Efficacy assessment was performed 90 days after the initiation of treatment. Primary outcome 
measurements were change in monthly migraine days as well as the percentage of subjects having at 
least a 50% reduction in monthly migraine days at month three compared to the run-in baseline month. 
The study showed that monthly migraine days were reduced by 29.7% whereas in the sham group an 
increase of 4.9% was observed. While the difference between month three and the run-in month was 
significant, the difference between both groups failed to reach significance (p=0.054) due to the high 
standard deviation of the data. In line with these findings the 50% responder rate was higher in the 
verum than in the sham group. In both study arms no adverse events were observed.  
In summary the available data suggest that eTNS provides an effective treatment option for the 
preventive and perhaps also acute treatment of migraine. Nevertheless larger studies are clearly needed 
to confirm these results.  
 
Occipital nerve stimulation 
The occipital nerve stimulation (ONS) was initially developed for the treatment of cluster headache but 
its indication was later expanded to migraine. The rationale for stimulation of the occipital nerve is 
based on the fact that the trigeminal and occipital nerves converge in the trigeminocervical complex, in 
particular at the level of C2, where they share the same nuclei(24). This anatomical situation allows a 
functional interaction and a mutual modulation of incoming signals of the trigeminal and occipital 
nerves before the nociceptive signals proceed to higher processing centers of the CNS(25-29). This 
modulating interaction is thought to be the basis for the efficacy of the (pharmacological) greater 
occipital nerve block(30, 31). However, the exact effect of the neurostimulation of the occipital nerve 
and its influence on pain perception remains to be elucidated. 
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ONS in cluster headache 
Several small open-label studies have suggested efficacy of ONS in chronic cluster headache(32-36) but 
to date no RCTs exist to confirm the obtained findings. In all of these studies patients experienced a 
significant reduction of attack frequency reaching in some patients up to 90% allowing many of them a 
reduction of their preventive medication. However, all of these studies had no sham control group so 
that results have to be interpreted with caution. Another shortcoming has long been the lack of long-
term data in regard to efficacy and safety of the intervention. Recently data has been published that 
suggest that the observed effects are sustainable with observational periods of up to 9 years(33, 37-39). 
These studies focused on severely affected patients with refractory chronic cluster headache, but again, 
these studies are observational without a sham control group. A RCT that would address the long-term 
effect and safety does not yet exist. 
 
ONS in migraine 
In contrast, RCT's investigating the efficacy of ONS in migraine do exist. In the large sham-controlled trial 
published by Silberstein et al. patients with chronic migraine were randomized in a 2:1 scheme with 105 
patients allocated to the active and 52 patients to the sham group(40). Electrodes were implanted uni- 
or bilaterally depending on the distribution of headache. Stimulation was performed using the IPG 
Genesis® system (St. Jude Medical Neuromodulation). Patients allocated to the sham group received a 
sham programmer that did not communicate with the IPG Genesis® system. Following a 1-month 
baseline period treatment was performed over 12 weeks. Primary outcome parameter was the mean 
daily intensity with a responder being a patient that had a reduction of at least 50%. The study did not 
meet its primary endpoint. From all patients allocated to the active group only 17.1% (18 patients) were 
classified as responders while in the sham group this was the case in 13.5% (7 patients) of patients. In 
contrast, the authors observed a significant reduction in headache days and migraine-related disability. 
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 In the open-label extension phase of the same study all patients that decided to continue received 
active stimulation over an additional period of 40 weeks(41). In total 157 patients were included in the 
final intention to treat analysis. In this extension study 47.8% of patients achieved a 50% response and 
headache frequency was significantly reduced(41). However, despite the positive outcome of this 
extension study the results have to be interpreted with caution due to the open-label design.  
 
In addition to these considerations regarding the efficacy of ONS in cluster headache and migraine ONS 
is not unproblematic as complications such as infections and lead migration are relatively common(42) 
leading to a temporal withdrawal of its approval by regulatory authorities in some countries.  
 
Single-pulse transcranial magnetic stimulation 
Single-pulse transcranial magnetic stimulation (sTMS) consists of a single magnetic pulse applied to the 
scalp and underlying cortex via a portable device.  
The thought that sTMS could be effective in the acute treatment of migraine with aura originated with 
the observation made in in vivo experiments that a wave of cortical neuronal depolarization, the cortical 
spreading depression (CSD), which is likely to be the underlying cause of the aura(43), could potentially 
depolarize meningeal nociceptors and thereby induce migraine pain(44). Based on this assumption 
Holland et al. showed that sTMS is able to disrupt CSD(45, 46). These observations let to the rationale 
that sTMS could be able to abort a migraine attack if sTMS was applied once the aura initiated.  
This hypothesis was tested in a randomized, double-blind, parallel-group, sham-controlled trial(47). In 
this study 201 patients were allocated to either active stimulation (sTMS) or sham. Upon stimulation, 
the device (Cerena Transcranial Magnetic Stimulator, Neuralieve) delivered a single magnetic field pulse 
of 0.9 T with a rise time of 180 μs and a total pulse length of under 1 ms and patients were instructed to 
apply 2 pulses delivered 30 s apart below the occipital bone. Patients initiated stimulation as soon as 
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possible after aura began and within 1 h of aura onset. Primary endpoint was the proportion of patients 
that were pain free at 2 h post-treatment. The study revealed that the proportion of patients being pain-
free at 2 h was significantly higher in those receiving active stimulation (39%) compared to those in the 
sham group (22%).  
 
In addition to its utility in the acute treatment of migraine attacks, sTMS has been studied as a 
preventive treatment (ESPOUSE study)(48). The rationale for expanding the study population to patients 
with and without aura was based on the observation that TMS can alter modulatory thalamocortical 
pathways suggesting a potential efficacy regardless of the presence of migraine aura(46). In this 
prospective study patients stimulated with the SpringTMS device (eNeura) over the occiput delivering 
four pulses twice daily over 3 months with the same parameters used in the preceding study described 
above. In addition to this preventive protocol, patients were allowed to treat an acute attack with 3 
consecutive pulses which could be repeated up to 2 times if necessary. Primary endpoint was the mean 
reduction in headache days from baseline to the 4-week period extending between weeks 9-12. As a 
comparator the authors chose a performance goal (statistically derived placebo response) which was 
based on the placebo responses observed in one device study and two clinical trials evaluating the 
efficacy of topiramate in the preventive treatment of migraine.  
The study revealed a significant reduction of headache days from baseline compared to the 
performance goal. Likewise, the 50% responder rate of 46% in the responder group was significantly 
higher than the 20% of the performance goal. As in the previous study only few adverse events and no 
severe adverse events were observed(48). 
 
Taken together, current evidence suggests that sTMS may be an effective and well-tolerated treatment 
option for the acute and preventive treatment of migraine.  
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Repetitive-pulse transcranial magnetic stimulation 
The rationale behind using repetitive-pulse transcranial magnetic stimulation (rTMS) for the preventive 
treatment of migraine was basically the same as for sTMS, namely the modulation of cortical 
excitability(49-51). While this seems a solid approach as most preventive medications inhibit cortical 
excitability(52), the influence of rTMS on cortical excitability appears to be more complex as the 
modulating influence depends on the pulse frequency. While rTMS at high frequency (20 Hz) increases 
cortical excitability, stimulation at low frequency (1Hz) has the opposite effect(53, 54). 
Information obtained from several clinical studies that aimed at assessing its efficacy for the preventive 
treatment of migraine have provided inconsistent results that are even contradicting the findings of the 
studies described above. In addition to the importance of using the appropriate stimulation frequency, 
the location of the stimulation seems to be at least equally important.  
In the sham-controlled study performed by Misra et al.(55), 100 patients were randomized to either 
active rTMS or sham. Active stimulation consisted of 600 pulses delivered at 10 Hz in 10 trains over 412 s 
applied over the motor cortex at the hot spot of the right abductor digiti minimi. Primary endpoint was 
the reduction in headache frequency and severity of at least 50 % after 1 month of daily stimulation. The 
study showed that compared to baseline headache frequency was reduced 78.7% in the active group 
compared to 33.3% in the sham group and headache severity was improved by 76.6% in the active 
group compared to 27.1% in the sham group. Therefore, the data suggest that 10 Hz rTMS at this 
particular site seems to be effective for the preventive treatment of migraine.  
Brighina et al.(56) made similar observations in their sham-controlled study when rTMS was applied 
with a frequency of 20 Hz (10 trains of 2 s duration) at the dorsolateral prefrontal cortex. However, the 
findings of this study have to be taken with caution as they are based on the observations made on 11 
patients. 
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In contrast to these findings, Teepker et al.(57) analyzed the efficacy of low frequency rTMS for the 
preventive treatment of migraine in a sham-controlled study. Active stimulation was provided over 5 
consecutive days in 2 trains consisting of 500 pulses delivered at a frequency of 1 Hz over the vertex. 
Primary endpoint was the reduction of migraine attacks during the 8-week follow-up compared to 
baseline. The study showed that while the number of migraine attacks was reduced significantly in the 
active group, the difference to the response observed in the sham group failed to reach statistical 
significance. These findings suggest that low-frequency stimulation is not effective in the preventive 
treatment of migraine. However, if the lack of efficacy is due to an inappropriate stimulation frequency 
or the wrong site of stimulation remains to be elucidated.  
In line with these results, Conforto et al.(58) showed that rTMS applied in 23 sessions over 8 weeks on 
the dorsolateral prefrontal cortex had no significant effect on headache days in patients with chronic 
migraine. Interestingly, in this study stimulation was performed at high frequency (10 Hz) therefore 
contradicting the findings obtained when stimulation was performed over the motor cortex at the hot 
spot of the right abductor digiti minimi. 
Summarizing the available data on rTMS, the data shows that high frequency rTMS (10 Hz) over the 
motor cortex at the hot spot of the right abductor digiti minimi is effective in preventing migraine 
attacks while low frequency stimulation (1 Hz) over the vertex is not. Data on rTMS over the dorsolateral 
prefrontal cortex is inconsistent as two studies using high frequency stimulation showed opposing 
results. Given this body of evidence further sham-controlled studies that would identify the appropriate 
site and frequency of rTMS are clearly needed before definitive conclusions on the efficacy in preventing 
migraine attacks can be drawn.  
 
Conclusion 
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Neurostimulation techniques have remarkably expanded the therapeutic toolbox of the neurologist 
treating primary headaches, in particular migraine and cluster headache. Their main advantage 
compared to current pharmacological acute and preventive treatment options is their superior side-
effect profile. However, regarding their efficacy many studies have significant limitations as some of 
them have an open-label design or a problematic sham device. Beyond that, most studies do not assess 
the efficacy of the blinding by asking patients at the end of the study if they assume they were in the 
treatment or the sham arm of the study. Based on data obtained exclusively from randomized, sham-
controlled trials, efficacy in primary headaches has been proven for most described devices. In detail, for 
cluster headache, nVNS has been proven effective in the acute treatment of episodic cluster headache 
attacks while SPG stimulation is effective in the acute and preventive treatment. In migraine, sTMS has 
been proven effective in the acute treatment of migraine and high-frequency rTMS significantly reduced 
headache frequency and severity. The current body of evidence clearly suggests that more randomized, 
sham-controlled studies are needed to confirm some of the positive results observed in open-label 
trials.  
 
Expert commentary 
While neuromodulation techniques play an increasingly important role as an expansion to currently 
available pharmacological treatments, evidence of most of the techniques remain problematic, the main 
reason being the difficulty in designing an adequate sham device that would mimic noises and 
perceptions during stimulation without inducing a clinically meaningful effect. Unfortunately, with the 
creation and improvement of adequate sham devices the data proving efficacy of some 
neuromodulation techniques has become less convincing so that the initially high expectations could not 
be met. Nevertheless most of these techniques have now earned their place in the treatment of primary 
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headaches, in particular in refractory cases. Nevertheless, research activities in this area will have to 
focus on an improvement of sham-devices where this is possible. Beyond that further randomized, 
sham-controlled studies are required to confirm positive results seen in open-label trials. In addition, it 
may be assumed that investigations regarding their efficacy have not yet reached the end of the road as 
new therapeutic areas, as for example their utility in indomethacin-sensitive headaches, are likely to be 
revealed in the near future. 
 
Five-year view 
It may be assumed that research and development of neurostimulation devices will continue on a high 
pace over the next years. The most significant challenge of these studies will be the development of 
improved sham-devices as this has been the main shortcoming of current studies and probably a 
significant reason for the frequently conflicting results.  
It can be expected that those devices exclusively tested in open-label studies will be studied for the 
efficacy in randomized, sham-controlled trials. Beyond that novel devices with entirely different 
mechanisms of action may become available(59, 60). Finally, the expansion of clinical trials on other 
primary headaches such as the indomethacin-responsive headaches is expected as preliminary results of 
some of the devices revealed promising results and these headache syndromes frequently lead to a 
significant reduction of quality of life as treatment options are limited and commonly associated with 
side-effects that require their discontinuation.  
  
Key issues 
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• Neurostimulation techniques expand the therapeutic armamentarium of primary headaches, in 
particular migraine and cluster headache.  
• Non-invasive vagal nerve stimulation (nVNS) has been proven effective in the acute treatment of 
cluster headache attacks in episodic cluster headache. Randomized-controlled trials for the 
acute and preventive treatment failed to prove an efficacy. 
• Exploratory studies suggest that nVNS could be effective in the treatment of indomethacin-
responsive headaches.  
• Sphenopalatine ganglion (SPG) stimulation is effective in the acute and preventive treatment of 
chronic cluster headache. 
• External trigeminal nerve stimulation (eTNS) has been tested in an RCT for the preventive 
treatment of migraine but failed to be effective when compared to placebo. 
• Occipital nerve stimulation (ONS) has been shown to be ineffective in chronic migraine as the 
RCT failed to meet its primary endpoint (reduction in attack severity by ≥ 50%). While the 
authors observed a significant reduction in headache days a new RCT is required until efficacy 
can be assumed. For its efficacy in cluster headache many open-label trials but no RCTs exist. A 
convincing conclusion regarding its clinical efficacy in cluster headache is therefore not possible.  
• Single-pulse transcranial magnetic stimulation has been proven effective for the acute 
treatment of migraine. For its efficacy in the preventive treatment of migraine no sham-
controlled RCT exists.  
• Repetitive transcranial magnetic stimulation has been proven effective in an RCT if stimulation is 
provided at a high frequency (10 Hz). In contrast low-frequency stimulation (1 Hz) has not been 
proven effective.  
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